中国肺癌杂志2024，Vol.27Issue(11)：849-854,6.DOI:10.3779/j.issn.1009-3419.2024.106.30
ALK融合阳性非小细胞肺癌新辅助靶向治疗的进展
Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer
孙伟臻 1周宇桁 1林耀彬 1冯寿铖 1龙浩1
作者信息
- 1. 510000 广州,中山大学肿瘤防治中心胸外科,华南肿瘤学国家重点实验室
- 折叠
摘要
Abstract
Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death worldwide,with anaplastic lymphoma kinase(ALK)fusion mutations accounting for approximately 4％-9％of cases.In recent years,there are increasing clinical evidences suggesting that the combination of ALK inhibitors with surgical treatment holds significant potential for clinical application in resectable early and locally advanced non-small cell lung cancer(NSCLC)patients.This review aims to summarize the advances in neoadjuvant targeted therapy for ALK fusion positive NSCLC and dis-cuss its advantages and challenges in clinical practice.关键词
肺肿瘤/ALK融合阳性/新辅助治疗/靶向治疗Key words
Lung neoplasms/ALK-positive/Neoadjuvant therapy/Targeted therapy引用本文复制引用
孙伟臻,周宇桁,林耀彬,冯寿铖,龙浩..ALK融合阳性非小细胞肺癌新辅助靶向治疗的进展[J].中国肺癌杂志,2024,27(11):849-854,6.
